Phase II Study of Bladder Cancer Using Novel Tumor Antigens for Prevention of the Recurrence for Bladder Cancer After TUR-Bt
DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified
using genome-wide expression profile analysis by the use of cDNA microarray in our previous
studies. The investigators have determined the HLA-A*2402 restricted epitope peptides
derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed
strong IFN-g production when stimulated with the appropriate targets expressed the
appropriate protein and HLA-A*2402. Furthermore, when vaccinated these peptides, specific
CTLs were determined after the vaccination. Therefore we focused on the prevention of the
recurrence of the bladder cancer after surgery using these peptides.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Recurrence rate after surgery (TUR-BT)
Tomoaki Fujioka, M.D. & Ph.D.
Department of Urology, Iwate Medical University
Japan: Ministry of Health, Labor and Welfare